Last reviewed · How we verify
Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers
Approved treatments
- Rinvoq · AbbVie Inc.
JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers patent landscape — cliff calendar, originator estates, attackable patents
- Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers treatment landscape brief
- Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers treatment updates RSS
Frequently asked questions about Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers
What drugs treat Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers?
Tracked treatments include Rinvoq.
What is the treatment for Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers?
Standard treatment for Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers includes Rinvoq. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers patent cliff · Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers CI report
- Treatment: Rinvoq · AbbVie Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing